Role of endoscopy in gastroesophageal reflux disease

Abstract

Gastroesophageal reflux disease is a condition due to reflux of stomach content in the esophagus causing trouble symptoms or complications or both. GERD is a clinical diagnosis and typically presents with a heartburn and/or regurgitation and a positive response to antacid secretory medications. GERD is the leading outpatient diagnosis among all gastrointestinal disorders in the United States. Approximately 40% of population report occasional symptoms of GERD whereas 10-20% of patients will have symptoms at least once in a week. Recent guidelines from gastrointestinal societies such as American College of Gastroenterology, American Society for Gastrointestinal Endoscopy and American College of Physicians have laid out specific indications regarding role of esophagogastroduodenoscopy in GERD. Despite these recommendations, studies have revealed that one-fifth to two-fifth EGDs may not be clinically indicated, especially where open access endoscopy referral system is used. Traditionally, GERD has been thought to be a disease of the western world. Prevalence rates had been estimated to be lower in Asia when compared to that of the Western Countries. Few recent epidemiological studies in India showed the prevalence of reflux disease in India to be between 8-24%, which is comparable to the western world. The use of EGDs becomes more critical for developing countries such as India where prevalence of GERD and BE is comparable to the western countries but have limited resources. In addition to direct cost for an EGD, it burdens economy with indirect costs such as time off from the work, transportation and any procedural complications. Risk stratifying patients with GERD may therefore prevent unnecessary procedures, harms and costs. The aim of this paper is to review the existing evidence on the role of endoscopy in GERD.

Key words

Barrett’s esophagus - endoscopy - gastroesophageal reflux disease

• References

• 1 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
• 2 Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005;54:710-7.
• 3 Locke GR 3 rd , Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3 rd . Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
• 4 Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
• 5 Charles RJ, Cooper GS, Wong RC, Sivak MV Jr, Chak A. Effectiveness of open-access endoscopy in routine primary-Care practice. Gastrointest Endosc 2003;57:183-6.
• 6 Sharma P, Wani S, Romero Y, Johnson D, Hamilton F. Racial and geographic issues in gastroesophageal reflux disease. Am J Gastroenterol 2008;103:2669-80.
• 7 Bhatia SJ, Reddy DN, Ghoshal UC, Jayanthi V, Abraham P, Choudhuri G, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: Report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol 2011;30:118-27.
• 8 Kumar S, Shivalli S. Prevalence, perceptions and profile of gastroesophageal reflux disease in a rural population of North Bihar. Natl J Community Med 2014;5:214-8.
• 9 Chang CY, Lee YC, Lee CT, Tu CH, Hwang JC, Chiang H, et al. The application of Prague C and M criteria in the diagnosis of Barrett’s esophagus in an ethnic Chinese population. Am J Gastroenterol 2009;104:13-20.
• 10 Akiyama T, Inamori M, Akimoto K, Iida H, Mawatari H, Endo H, et al. Risk factors for the progression of endoscopic Barrett’s epithelium in Japan: A multivariate analysis based on the Prague C and M Criteria. Dig Dis Sci 2009;54:1702-7.
• 11 Punia RS, Arya S, Mohan H, Duseja A, Bal A. Spectrum of clinico-pathological changes in Barrett oesophagus. J Assoc Physicians India 2006;54:187-9.
• 12 Wani IR, Showkat HI, Bhargav DK, Samer M. Prevalence and risk factors for barrett’s esophagus in patients with GERD in Northern India; do methylene blue-directed biopsies improve detection of Barrett’s esophagus compared the conventional method? Middle East J Dig Dis 2014;6:228-36.
• 13 Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87.e1-3.
• 14 Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. Scand J Gastroenterol 2005;40:275-85.
• 15 Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
• 16 Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-100.
• 17 Richter JE. Diagnostic tests for gastroesophageal reflux disease. Am J Med Sci 2003;326:300-8.
• 18 Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
• 19 Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
• 20 Rath HC, Timmer A, Kunkel C, Endlicher E, Grossmann J, Hellerbrand C, et al. Comparison of interobserver agreement for different scoring systems for reflux esophagitis: Impact of level of experience. Gastrointest Endosc 2004;60:44-9.
• 21 Ismail-Beigi F, Pope CE 2 nd . Distribution of the histological changes of gastroesophageal reflux in the distal esophagus of man. Gastroenterology 1974;66:1109-13.
• 22 Ismail-Beigi F, Horton PF, Pope CE 2 nd . Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970;58:163-74.
• 23 Vieth M, Peitz U, Labenz J, Kulig M, Nauclér E, Jaspersen D, et al. What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett’s mucosa? Dig Dis 2004;22:196-201.
• 24 Calabrese C, Fabbri A, Bortolotti M, Cenacchi G, Areni A, Scialpi C, et al. Dilated intercellular spaces as a marker of oesophageal damage: Comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003;18:525-32.
• 25 Caviglia R, Ribolsi M, Maggiano N, Gabbrielli AM, Emerenziani S, Guarino MP, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005;100:543-8.
• 26 Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett’s esophagus: A systematic review and meta-analysis. Ann Thorac Surg 2009;87:655-62.
• 27 Lenglinger J, Riegler M, Cosentini E, Asari R, Mesteri I, Wrba F, et al. Review on the annual cancer risk of Barrett’s esophagus in persons with symptoms of gastroesophageal reflux disease. Anticancer Res 2012;32:5465-73.
• 28 Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003;138:176-86.
• 29 American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011;140:1084-91.
• 30 ASGE Standards of Practice Committee, Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012;76:1087-94.
• 31 Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2008;103:788-97.
• 32 Shaheen NJ, Weinberg DS, Denberg TD, Chou R, Qaseem A, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Upper endoscopy for gastroesophageal reflux disease: Best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 2012;157:808-16.
• 33 Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M, et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: A Netherlands cohort study. Gastroenterology 2013;145:96-104.
• 34 van Vilsteren FG, Pouw RE, Seewald S, Alvarez Herrero L, Sondermeijer CM, Visser M, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: A multicentre randomised trial. Gut 2011;60:765-73.
• 35 Gupta M, Iyer PG, Lutzke L, Gorospe EC, Abrams JA, Falk GW, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: Results from a US Multicenter Consortium. Gastroenterology 2013;145;1:79-86.
• 36 Qumseya BJ, Wang H, Badie N, Uzomba RN, Parasa S, White DL, et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett’s esophagus: A meta-analysis and systematic review. Clin Gastroenterol Hepatol 2013;11:1562-70.e1-2.
• 37 Sharma P, Hawes RH, Bansal A, Gupta N, Curvers W, Rastogi A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: A prospective, international, randomised controlled trial. Gut 2013;62:15-21.
• 38 Standards of Practice Committee, Egan JV, Baron TH, Adler DG, Davila R, Faigel DO, et al. Esophageal dilation. Gastrointest Endosc 2006;63:755-60.
• 39 Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251-5.
• 40 Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett’s esophagus: A systematic review. Am J Gastroenterol 2012;107:850-62.
• 41 Buskens CJ, Westerterp M, Lagarde SM, Bergman JJ, ten Kate FJ, van Lanschot, et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004;60:703-10.
• 42 Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: Outcomes of the UK National Halo RFA Registry. Gastroenterology 2013;145:87-95.
• 43 Probst A, Aust D, Märkl B, Anthuber M, Messmann H. Early esophageal cancer in Europe: Endoscopic treatment by endoscopic submucosal dissection. Endoscopy 2015;47:113-21.
• 44 Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc 2000;52:197-203.
• 45 Shaheen NJ, Green B, Medapalli RK, Mitchell KL, Wei JT, Schmitz SM, et al. The perception of cancer risk in patients with prevalent Barrett’s esophagus enrolled in an endoscopic surveillance program. Gastroenterology 2005;129:429-36.
• 46 Rubenstein JH, Saini SD, Kuhn L, McMahon L, Sharma P, Pardi DS, et al. Influence of malpractice history on the practice of screening and surveillance for Barrett’s esophagus. Am J Gastroenterol 2008;103:842-9.
• 47 Hassan C, Bersani G, Buri L, Zullo A, Anti M, Bianco MA, et al. Appropriateness of upper-GI endoscopy: An Italian Survey on Behalf of the Italian Society of Digestive Endoscopy. Gastrointest Endosc 2007;65:767-74.
• 48 Rossi A, Bersani G, Ricci G, Defabritiis G, Pollino V, Suzzi A, et al. ASGE guidelines for the appropriate use of upper endoscopy: Association with endoscopic findings. Gastrointest Endosc 2002;56:714-9.
• 49 Gonvers JJ, Burnand B, Froehlich F, Pache I, Thorens J, Fried M, et al. Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy unit. Endoscopy 1996;28:661-6.
• 50 Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006;23:1473-7.
• 51 Barrison AF, Jarboe LA, Weinberg BM, Nimmagadda K, Sullivan LM, Wolfe MM. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001;111:469-73.